SETD2 and nonpapillary renal cell carcinoma: We used an existing isogenic SETD2 KO model in the 786‐O ccRCC cell line that we created previously [22] and a second ccRCC cell line derived from a treatment refractory Mayo Clinic ccRCC patient [26] (referred to as RCJ‐41T1) with SETD2 deficiency engineered using CRIPSR/CAS9 (similar to the RPTEC approach).